Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
2018 ◽
Vol 72
(5)
◽
pp. S33-S36
◽
2017 ◽
Vol 10
(5)
◽
pp. 337-350
◽
2004 ◽
Vol 66
◽
pp. S126-S127
◽
2002 ◽
Vol 2
(1)
◽
pp. 20-24
◽
2008 ◽
Vol 1
(1)
◽
pp. 2-6
◽
2012 ◽
Vol 8
(3)
◽
pp. 172-181
◽